Compare ATRA & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRA | FBIO |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 113.9M |
| IPO Year | 2014 | N/A |
| Metric | ATRA | FBIO |
|---|---|---|
| Price | $15.37 | $4.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $25.00 | $16.50 |
| AVG Volume (30 Days) | 90.5K | ★ 689.1K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $151,930,000.00 | $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | $7.41 | ★ N/A |
| Revenue Growth | ★ 51.27 | N/A |
| 52 Week Low | $5.01 | $1.33 |
| 52 Week High | $19.15 | $4.34 |
| Indicator | ATRA | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 71.30 |
| Support Level | $14.27 | $4.02 |
| Resistance Level | $19.15 | $4.34 |
| Average True Range (ATR) | 1.45 | 0.22 |
| MACD | -0.40 | 0.05 |
| Stochastic Oscillator | 19.26 | 77.67 |
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.